CORRECTED-UPDATE 2-Ebola therapy hopes shift to small California biotech
By Akane Otani and Bill Berkrot
Aug 4 (Reuters) - Hopes of finding a treatment for the deadly Ebola virus shifted on Monday to a small California-based biotech company whose experimental drug has been used to treat two American missionary workers.
The drug, developed by Mapp Biopharmaceutical Inc, was used to treat two aid workers, one from the Samaritan's Purse group and the other from Christian mission group SIM USA, who were exposed to the disease in Liberia, according to a U.S. government health official.
The official said the treatment was administered in Liberia.
One of the aid workers, Dr Kent Brantly, returned to the United States on Saturday for medical care, and his colleague Nancy Writebol is due to fly back to the country via medical aircraft on Tuesday.
Samaritan's Purse said both the aid workers received the experimental treatment while in Liberia.
News of the treatment, first reported by CNN, punctured a share price rally in Canada's Tekmira Pharmaceuticals, whose own experimental Ebola treatment had progressed to human trials. The severity of the current outbreak in Africa, in which more than 800 people have died, has raised investor expectations that Tekmira's treatment might move more quickly toward regulatory approval.
The treatment developed by Mapp, called ZMapp, had only been tested in monkeys. Treatment with experimental drugs that have not gone through the customary series of clinical trials in humans to determine safety and efficacy is highly unusual. Continued...